Skip to Content

Odomzo Approval History

FDA Approved: Yes (First approved July 24, 2015)
Brand name: Odomzo
Generic name: sonidegib
Dosage form: Capsules
Company: Novartis Pharmaceuticals Corporation
Treatment for: Basal Cell Carcinoma

Odomzo (sonidegib) is a hedgehog pathway inhibitor indicated for the treatment of locally advanced basal cell carcinoma (BCC).

Development History and FDA Approval Process for Odomzo

DateArticle
Jul 24, 2015Approval FDA Approves Odomzo (sonidegib) for Locally Advanced Basal Cell Carcinoma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide